FrancophonIA/ELRC3.0 huggingface dataset:
English: Zoledronic acid 4 mg was also studied in a double-blind, randomised, placebo-controlled trial in 228 patients with documented bone metastases from breast cancer to evaluate the effect of 4 mg zoledronic acid on the skeletal related event (SRE) rate ratio, calculated as the total number of SRE events (excluding hypercalcaemia and adjusted for prior fracture), divided by the total risk period.
Croatian: Zoledronatna kiselina od 4 mg također se ispitivala u dvostruko slijepom, randomiziranom, placebom kontroliranom ispitivanju u 228 bolesnika s potvrđenim koštanim metastazama karcinoma dojke da bi se procijenio učinak zoledronatne kiseline u dozi od 4 mg na omjer stope koštanih događaja izračunatog kao ukupni broj koštanih događaja (bez hiperkalcemije i prilagođen s obzirom na prethodne prijelome) podijeljen s ukupnim rizičnim razdobljem.
English: Zoledronic acid has been associated with reports of renal dysfunction.
Croatian: Zoledronatna kiselina povezuje se s prijavama poremećaja funkcije bubrega.
English: MARKETING AUTHORISATION NUMBER(S) EU/1/13/834/001- 1vial pack EU/1/13/834/002- 4 vial pack EU/1/13/834/003- 10 vial pack
Croatian: EU/1/13/834/001- pakiranje s 1 bočicom EU/1/13/834/002- pakiranje sa 4 bočice EU/1/13/834/003- pakiranje s 10 bočica
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 16.01.2014
Croatian: DATUM PRVOG ODOBRENJA/DATUM OBNOVE ODOBRENJA
English: The active substance in Zoledronic Acid Accord is zoledronic acid, which belongs to a group of substances called bisphosphonates.
Croatian: Djelatna tvar u Zoledronatnoj kiselini Accord je zoledronatna kiselina, koja pripada skupini tvari koje se zovu bisfosfonati.
English: Zoledronic acid treatment should be resumed at the same dose as that given prior to treatment interruption.
Croatian: Liječenje zoledronatnom kiselinom treba nastaviti istom dozom koja se davala prije prekida liječenja.
English: In patients with bone metastases presenting with mild to moderate renal impairment prior to initiation of therapy, which is defined for this population as CLcr 30-60 ml/min, the following zoledronic acid dose is recommended (see also section 4.4):
Croatian: U bolesnika s metastazama u kostima koji prije početka liječenja imaju blago do umjereno oštećenje funkcije bubrega, koje se u ove populacije definira kao klirens kreatinina od 30 do 60 ml/min, preporučuje se sljedeća doza zoledronatne kiseline (vidjeti također dio 4.4):
English: Reduced levels of calcium in the blood (hypocalcaemia), sometimes leading to muscle cramps, dry skin, burning sensation, have been reported in patients treated with Zoledronic Acid Accord.
Croatian: Smanjene razine kalcija u krvi (hipokalcemija), što ponekad dovodi do mišićnih grčeva, suhe kože, osjećaja peckanja, zabilježene su u bolesnika koji su liječeni Zoledronatnom kiselinom Accord.
English: The following are the important identified risks with zoledronic acid in the approved indications: Renal function impairment, osteonecrosis of the jaw, acute phase reaction, hypocalcaemia, atrial fibrillation, anaphylaxis, interstitial lung disease.
Croatian: Utvrđeni su sljedeći važni rizici primanja zoledronatne kiseline u odobrenim indikacijama: oštećenje funkcije bubrega, osteonekroza čeljusti, reakcija akutne faze, hipokalcemija, fibrilacija atrija, anafilaksija, intersticijska bolest pluća.
English: Based on the review of both clinical trial and post-marketing cases, there is sufficient evidence to support an association between zoledronic acid therapy, the reported event of hypocalcaemia, and the secondary development of cardiac arrhythmia.
Croatian: Na osnovu ocjenjivanja kliničkog ispitivanja i slučajeva nakon stavljanja lijeka na tržište postoji dovoljno dokaza koji ukazuju na povezanost između terapije zoledronatnom kiselinom, prijavljenih slučajeva hipokalcemije i posljedičnog razvoja srčane aritmije.
English: Caution is advised when Zolendronc Acid Accord is administered with medicinal products known to cause hypocalcaemia, as they may have a synergistic effect resulting in severe hypocalcaemia (see section 4.5).
Croatian: Savjetuje se oprez kod primjene Zoledronatne kiseline Accord s lijekovima za koje je poznato da uzrokuju hipokalcemiju budući da mogu imati sinergistički učinak s posljedičnom teškom hipokalcemijom (vidjeti dio 4.5).
English: Excipients: mannitol (E421), sodium citrate and water for injections.
Croatian: Pomoćne tvari: manitol (E421), natrijev citrat i voda za injekcije.
English: Convulsions, hypoaesthesia and tetany (secondary to hypocalcaemia)
Croatian: konvulzije, hipoestezija, tetanija (uzrokovana hipokalcemijom)
English: Pain in extremities, arthralgia, musculoskeletal pain
Croatian: bol u ekstremitetima, artralgija, mišićno-koštana bol
English: What Zoledronic Acid Accord looks like and contents of the pack Zoledronic Acid Accord is supplied as a liquid concentrate in a vial.
Croatian: Kako Zoledronatna kiselina Accord izgleda i sadržaj pakiranja Zoledronatna kiselina Accord isporučuje se kao tekući koncentrat u bočici.
English: From a microbiological point of view, the diluted solution for infusion should be used immediately.
Croatian: S mikrobiološkog stajališta, razrijeđena otopina za infuziju treba se odmah primijeniti.
English: Increases in serum creatinine also occur in some patients with chronic administration of zoledronic acid at recommended doses for prevention of skeletal related events, although less frequently.
Croatian: U nekih bolesnika dolazi do povišenja kreatinina u serumu i kod kronične primjene zoledronatne kiseline u dozama koje se preporučuju za sprječavanje koštanih događaja, iako manje često.
English: 3.8 ml for 3.0 mg dose
Croatian: - 3,8 ml za dozu od 3,0 mg
English: Median time to relapse (re-increase of albumin-corrected serum calcium ≥ 2.9 mmol/l) was 30 to 40 days for patients treated with zoledronic acid versus 17 days for those treated with pamidronate 90 mg (p-values: 0.001 for 4 mg and 0.007 for 8 mg zoledronic acid).
Croatian: Medijan vremena do relapsa (ponovnog povišenja kalcija u serumu korigiranog za albumin ≥ 2,9 mmol/l) iznosio je 30 do 40 dana u bolesnika liječenih zoledronatnom kiselinom za razliku od 17 dana u onih liječenih pamidronatom u dozi od 90 mg (p-vrijednosti: 0,001 za 4 mg i 0,007 za 8 mg zoledronatne kiseline).
English: In view of the potential impact of zoledronic acid on renal function, the lack of clinical safety data in patients with severe renal impairment (in clinical trials defined as serum creatinine ≥ 400 µmol/l or ≥ 4.5 mg/dl for patients with TIH and ≥ 265 µmol/l or ≥ 3.0 mg/dl for patients with cancer and bone metastases, respectively) at baseline and only limited pharmacokinetic data in patients with severe renal impairment at baseline (creatinine clearance < 30 ml/min), the use of zoledronic acid is not recommended in patients with severe renal impairment.
Croatian: S obzirom na mogući utjecaj zoledronatne kiseline na funkciju bubrega, nedostatak kliničkih podataka o sigurnosti primjene u bolesnika s teškim oštećenjem funkcije bubrega (u kliničkim ispitivanjima definiranim kao kreatinin u serumu ≥ 400 μmol/l ili ≥ 4,5 mg/dl u bolesnika s hiperkalcemijom izazvanom tumorom, odnosno ≥ 265 μmol/l ili ≥ 3,0 mg/dl u bolesnika s rakom i metastazama u kostima) na početku liječenja i ograničene farmakokinetičke podatke u bolesnika s teškim oštećenjem funkcije bubrega (klirens kreatinina <30 ml/min) na početku liječenja, ne preporučuje se primjena zoledronatne kiseline u bolesnika s teškim oštećenjem funkcije bubrega.
English: • Difficulty in breathing with wheezing or coughing.
Croatian: • otežano disanje uz piskanje u plućima ili kašljanje.
English: The safety margins relative to renal effects were narrow in the long-term repeat-dose parenteral animal studies but the cumulative no adverse event levels (NOAELs) in the single dose (1.6 mg/kg) and multiple dose studies of up to one month (0.06-0.6 mg/kg/day) did not indicate renal effects at doses equivalent to or exceeding the highest intended human therapeutic dose.
Croatian: Dugotrajna ispitivanja ponovljene parenteralne doze u životinja pokazala su uzak raspon sigurnosti s obzirom na učinke na bubrege, ali najviša kumulativna doza koja ne uzrokuje oštećenje (NOAEL) u ispitivanjima jednostruke doze (1,6 mg/kg) i višestrukih doza u trajanju do jednog mjeseca (0,060,6 mg/kg na dan) nije imala učinke na bubrege pri dozama jednakima ili višima od najviše terapijske doze namijenjene ljudima.
English: Patients being treated with Zoledronic Acid Accord should not be treated with Aclasta or any other bisphosphonate concomitantly, since the combined effects of these agents are unknown.
Croatian: Bolesnici koji se liječe Zoledronatnom kiselinom Accord ne smiju istodobno uzimati Aclastu ili bilo koji drugi bisfosfonat, budući da nisu poznati kombinirani učinci tih lijekova.
English: • To prepare an infusion solution containing 4 mg zoledronic acid, further dilute the Zoledronic Acid Accord concentrate (5ml) with 100 ml of calcium-free or other divalent cation-free infusion solution.
Croatian: • Da biste pripremili otopinu za infuziju koja sadrži 4 mg zoledronatne kiseline, dodatno razrijedite koncentrat Zoledronatne kiseline Accord (5 ml) sa 100 ml otopine za infuziju koja ne sadrži kalcij niti druge dvovalentne katione.
English: Caution is advised when zoledronic acid is administered with anti-angiogenic medicinal products, as an increase in the incidence of ONJ has been observed in patients treated concomitantly with these medicinal products.
Croatian: Savjetuje se oprez prilikom primjene zoledronatne kiseline sa antiangiogenim lijekovima budući da je zabilježena incidencija osteonekroze čeljusti u bolesnika istovremeno liječenih ovim lijekovima.
English: In the clinical trials, renal deterioration was defined as follows: For patients with normal baseline serum creatinine (< 1.4 mg/dl or < 124 µmol/l), an increase of 0.5 mg/dl or 44 µmol/l; For patients with abnormal baseline creatinine (> 1.4 mg/dl or > 124 µmol/l), an increase of 1.0 mg/dl or 88 µmol/l.
Croatian: U kliničkim je ispitivanjima pogoršanje funkcije bubrega bilo definirano na sljedeći način: povišenje vrijednosti kreatinina za 0,5 mg/dl ili 44 μmol/l, u bolesnika s normalnom početnom vrijednošću kreatinina u serumu (< 1,4 mg/dl ili < 124 μmol/l), povišenje vrijednosti kreatinina za 1,0 mg/dl ili 88 μmol/l, u bolesnika s poremećenom početnom vrijednošću kreatinina (> 1,4 mg/dl ili > 124 μmol/l).
English: The pain score for zoledronic acid was consistently below baseline and pain reduction was accompanied by a trend in reduced analgesics score.
Croatian: Rezultat na ljestvici bola za zoledronatnu kiselinu bio je dosljedno ispod početne razine, a smanjenje bola bilo je praćeno trendom smanjenja bodova za analgetike.
English: The following adverse reactions, listed in Table 1, have been accumulated from clinical studies and post-marketing reports following predominantly chronic treatment with 4 mg zoledronic acid:
Croatian: Sljedeće nuspojave navedene u tablici 1 prikupljene su iz kliničkih ispitivanja i prijava nakon stavljanja lijeka u promet, uglavnom kod kroničnog liječenja zoledronatnom kiselinom u dozi od 4 mg:
English: To assess the effects of 4 mg zoledronic acid versus pamidronate 90 mg, the results of two pivotal multicentre studies in patients with TIH were combined in a pre-planned analysis.
Croatian: Da bi se procijenili učinci zoledronatne kiseline u dozi od 4 mg u usporedbi s 90 mg pamidronata, u unaprijed planiranoj analizi kombinirali su se rezultati dva glavna multicentrična ispitivanja u bolesnika s hiperkalcemijom izazvanom tumorom.
English: During post-marketing experience the following reactions have been reported (frequency rare): Atypical subtrochanteric and diaphyseal femoral fractures (bisphosphonate class adverse reaction).
Croatian: U razdoblju nakon stavljanja lijeka u promet zabilježene su sljedeće reakcije (rijetke učestalosti): atipični suptrohanterični prijelomi i prijelomi dijafize bedrene kosti (nuspojava skupine bisfosfonata).
English: In most cases no specific treatment is required and the symptoms disappear after a short time (couple of hours or days).
Croatian: zimice i bolova u kostima, zglobovima i/ili mišićima; u većini slučajeva nije potrebno posebno liječenje, i simptomi nestaju nakon kratkog vremena (nekoliko sati ili dana).
English: * Includes vertebral and non-vertebral fractures ** Accounts for all skeletal events, the total number as well as time to each event during the trial NR-Not Reached
Croatian: ** Odnosi se na sve koštane događaje, njihov ukupni broj i vrijeme do svakog pojedinog događaja tijekom ispitivanja.
English: In Phase I dose finding studies in patients with mild to moderate tumour-induced hypercalcaemia (TIH), effective doses tested were in the range of approximately 1.2-2.5 mg.
Croatian: U ispitivanjima faze I, određivanja doze u bolesnika s blagom do umjerenom hiperkalcemijom izazvanom tumorom, djelotvorne ispitivane doze kretale su se u rasponu od približno 1,2 do 2,5 mg.
English: Blurred vision, scleritis and orbital inflammation
Croatian: zamagljen vid, skleritis i upala orbite
English: Proportion of patients with SREs (%) p-value
Croatian: Udio bolesnika s koštanim događajem (%) p-vrijednost Medijan
English: Patients must be maintained well hydrated prior to and following administration of zoledronic acid.
Croatian: Bolesnici moraju biti dobro hidrirani prije i nakon primjene zoledronatne kiseline.
English: In a pooled analysis of safety data from zoledronic acid registration trials for the prevention of skeletal-related events in patients with advanced malignancies involving bone, the frequency of renal impairment adverse events suspected to be related to zoledronic acid (adverse reactions) was as follows: multiple myeloma (3.2%), prostate cancer (3.1%), breast cancer (4.3%), lung and other solid tumours (3.2%).
Croatian: U analizi objedinjenih podataka o sigurnosti primjene zoledronatne kiseline iz registracijskih ispitivanja za sprječavanje koštanih događaja u bolesnika s uznapredovalom zloćudnom bolešću koja je zahvatila kosti, sumnjalo se da je učestalost nuspojave oštećenja funkcije bubrega povezana sa zoledronatnom kiselinom (nuspojava) na sljedeći način: multipli mijelom (3,2%), karcinom prostate (3,1%), karcinom dojke (4,3%), karcinom pluća i drugi solidni tumori (3,2%).
English: Cases of osteonecrosis of the jaw have been reported, predominantly in cancer patients treated with medicinal products that inhibit bone resorption, such as zoledronic acid (see section 4.4).
Croatian: Slučajevi osteonekroze čeljusti pretežno su zabilježeni u onkoloških bolesnika liječenih lijekovima koji inhibiraju resorpciju kosti, kao što je zoledronatna kiselina (vidjeti dio 4.4).
English: Asthenia, peripheral oedema, injection site reactions (including pain, irritation, swelling, induration), chest pain, weight increase, anaphylactic reaction/shock, urticaria
Croatian: astenija, periferni edemi, reakcije na mjestu primjene injekcije (uključujući bol, iritaciju, oteklinu i otvrdnuće), bol u prsištu, povećanje tjelesne težine, anafilaktična reakcija/šok, urtikarija
English: • Skin reactions (redness and swelling) at the infusion site, rash, itching.
Croatian: • kožne reakcije (crvenilo i oticanje) na mjestu primjene infuzije, osip, svrbež
English: Zoledronic acid is contraindicated in breast-feeding women (see section 4.3).
Croatian: Zoledronatna kiselina kontraindicirana je tijekom dojenja (vidjeti dio 4.3).
English: • As a consequence of low calcium values: irregular heart beat (cardiac arrhythmia; secondary to hypocalcaemia).
Croatian: • kao posljedica niskih razina kalcija: nepravilni otkucaji srca (srčana aritmija, uslijed hipokalcemije).
English: Do not receive Zoledronic Acid Accord:
Croatian: Ne smijete primati Zoledronatnu kiselinu Accord:
English: In one 3-year, randomised, double-blind controlled trial that evaluated the efficacy and safety of zoledronic acid 5 mg once yearly vs. placebo in the treatment of postmenopausal osteoporosis (PMO), the overall incidence of atrial fibrillation was 2.5% (96 out of 3,862) and 1.9% (75 out of 3,852) in patients receiving zoledronic acid 5 mg and placebo, respectively.
Croatian: U randomiziranom, dvostruko slijepom, kontroliranom ispitivanju u trajanju od 3 godine u kojem se ocjenjivala djelotvornost i sigurnost zoledronatne kiseline u dozi od 5 mg jedanput godišnje u usporedbi s placebom u liječenju postmenopauzalne osteoporoze (PMO), ukupna incidencija atrijske fibrilacije iznosila je 2,5% (96 od 3862) u bolesnica koje su primale zoledronatnu kiselinu u dozi od 5 mg i 1,9% (75 od 3852) u onih koje su primale placebo.
English: • The solution containing zoledronic acid is given as a single 15-minute intravenous infusion in a separate infusion line.
Croatian: • Otopina koja sadrži zoledronatnu kiselinu daje se kao jednokratna 15-minutna intravenska infuzija u zasebnoj infuzijskoj liniji.
English: • Keep Zoledronic Acid Accord out of the reach and sight of children.
Croatian: Zoledronatnu kiselinu Accord čuvajte izvan dohvata i pogleda djece.
English: • Urticaria.
Croatian: • koprivnjača.
English: Table 5: Proportion of complete responders by day in the combined TIH studies
Croatian: Tablica 5: Udio ispitanika s potpunim odgovorom prema danima u kombiniranim ispitivanjima liječenja hiperkalcemije izazvane tumorom
English: If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.
Croatian: Ako imate bilo kakvih dodatnih pitanja o uporabi ovog lijeka, obratite se svom liječniku, ljekarniku ili medicinskoj sestri.
English: • Zoledronic Acid Accord is given as a drip (infusion) into a vein which should take at least 15 minutes and should be administered as a single intravenous solution in a separate infusion line.
Croatian: • Zoledronatna kiselina Accord daje se u venu kao infuzija (drip) u trajanju od najmanje 15 minuta i mora se primijeniti kao jednokratna intravenska otopina kroz zasebnu infuzijsku liniju.
English: What you need to know before you are given Zoledronic Acid Accord 3.
Croatian: Što morate znati prije nego primite Zoledronatnu kiselinu Accord 3.
English: Diarrhoea, constipation, abdominal pain, dyspepsia, stomatitis, dry mouth
Croatian: proljev, zatvor, bolovi u trbuhu, dispepsija, stomatitis, suha usta
English: A subset had recurrence of symptoms when rechallenged with zoledronic acid or another bisphosphonate.
Croatian: U dijela tih bolesnika simptomi su se vratili nakon ponovnog izlaganja zoledronatnoj kiselini ili drugom bisfosfonatu.
English: Zoledronic acid 4 mg significantly reduced the proportion of patients experiencing at least one skeletal related event (SRE), delayed the median time to first SRE by > 5 months, and reduced the annual incidence of events per patient-skeletal morbidity rate.
Croatian: Zoledronatna kiselina u dozi od 4 mg značajno je smanjila udio bolesnika s najmanje jednim koštanim događajem, produljila medijan vremena do prvog koštanog događaja za više od 5 mjeseci i smanjila godišnju incidenciju događaja po bolesniku - stopu koštanog pobola.
English: In patients with mild to moderate renal impairment, reduced zoledronic acid doses are recommended (see section “Posology” above and section 4.4).
Croatian: U bolesnika s blagim do umjerenim oštećenjem funkcije bubrega preporučuju se snižene doze zoledronatne kiseline (vidjeti dio “Doziranje” iznad i dio 4.4).
English: Mannitol (E421) Sodium citrate Water for injections
Croatian: 6.1 Popis pomoćnih tvari manitol (E421) natrijev citrat voda za injekcije
English: What you need to know before you are given Zoledronic Acid Accord
Croatian: Što morate znati prije nego primite Zoledronatnu kiselinu Accord
English: Patients should have their serum creatinine levels assessed prior to each dose of zoledronic acid.
Croatian: Bolesnicima treba provjeriti razinu kreatinina u serumu prije svake primjene doze zoledronatne kiseline.
English: There was faster normalisation of corrected serum calcium at day 4 for 8 mg zoledronic acid and at day 7 for 4 mg and 8 mg zoledronic acid.
Croatian: Pronašla se brža normalizacija korigiranog kalcija u serumu 4. dana kod doze zoledronatne kiseline u dozi od 8 mg i 7. dana kod doze zoledronatne kiseline u dozi od 4 mg i 8 mg.
English: What Zoledronic Acid Accord is and what it is used for 2.
Croatian: Što je Zoledronatna kiselina Accord i za što se koristi 2.
English: This medicine contains less than 1 mmol sodium (23 mg) per vial, that is to say essentially ‘sodium-free'.
Croatian: Ovaj lijek sadrži manje od 1 mmol natrija (23 mg) po bočici, tj. zanemarive količine natrija.
English: In the zoledronic acid-treated group, statistically significant improvement in pain scores (using the Brief Pain Inventory, BPI) was seen at 4 weeks and at every subsequent time point during the study, when compared to placebo (Figure 1).
Croatian: Brief Pain Inventory - BPI) nakon 4 tjedna i pri svakom sljedećem mjerenju tijekom ispitivanja u usporedbi s placebom (slika 1).
English: Factors that may increase the potential for deterioration in renal function include dehydration, pre-existing renal impairment, multiple cycles of zoledronic acid and other bisphosphonates as well as use of other nephrotoxic medicinal products.
Croatian: Čimbenici koji mogu povećati mogućnost pogoršanja funkcije bubrega uključuju dehidraciju, postojeće oštećenje funkcije bubrega, višestruke cikluse liječenja zoledronatnom kiselinom i drugim bisfosfonatima, kao i uzimanje drugih nefrotoksičnih lijekova.
English: Hypomagnesaemia, hypokalaemia
Croatian: hipomagnezemija, hipokalemija
English: • Flu-like symptoms including arthritis and joint swelling.
Croatian: • Simptomi nalik gripi uključujući artritis i oticanje zglobova.
English: Treatment of adult patients with tumour-induced hypercalcaemia (TIH).
Croatian: Liječenje odraslih bolesnika s hiperkalcemijom izazvanom tumorom.
English: Instructions for preparing reduced doses of Zoledronic Acid Accord: Withdraw the appropriate volume of the liquid concentrate, as follows: o 4.4 ml for 3.5 mg dose o 4.1 ml for 3.3 mg dose o 3.8 ml for 3.0 mg dose
Croatian: Izvucite sljedeći odgovarajući volumen tekućeg koncentrata: o 4,4 ml za dozu od 3,5 mg o 4,1 ml za dozu od 3,3 mg o 3,8 ml za dozu od 3,0 mg
English: • High blood pressure, shortness of breath, dizziness, anxiety, sleep disturbances, taste disturbances, trembling, tingling or numbness of the hands or feet, diarrhoea constipation,
Croatian: • visok krvni tlak, nedostatak zraka, omaglica, tjeskoba, poremećaji spavanja, promjena osjeta okusa, drhtavica, trnci ili utrnulost šaka ili stopala, proljev, zatvor, bol u trbuhu, suha usta.
English: Pruritus, rash (including erythematous and macular rash), increased sweating
Croatian: svrbež, osip (uključujući eritematozni i makularni osip), pojačano znojenje
English: Do not mix Zoledronic Acid Accord concentrate with calcium-containing or other divalent cation-containing solutions such as lactated Ringer's solution.
Croatian: Nemojte miješati koncentrat Zoledronatne kiseline Accord s otopinama koje sadrže kalcij ili druge dvovalentne katione kao što je otopina Ringerovog laktata.
English: For storage conditions of the reconstituted solution for infusion, see section 6.3.
Croatian: Uvjete čuvanja razrijeđene otopine za infuziju vidjeti u dijelu 6.3.
English: What Zoledronic Acid Accord is and what it is used for
Croatian: Što je Zoledronatna kiselina Accord i za što se koristi
English: Factors that may increase the potential for deterioration in renal function include dehydration, pre-existing renal impairment, multiple cycles of zoledronic acid or other bisphosphonates, as well as concomitant use of nephrotoxic medicinal products or using a shorter infusion time than currently recommended.
Croatian: Čimbenici koji mogu povećati mogućnost propadanja funkcije bubrega uključuju dehidraciju, postojeće oštećenje funkcije bubrega, višestruke cikluse primanja zoledronatne kiseline ili drugih bisfosfonata, kao i istovremenu primjenu nefrotoksičnih lijekova ili kraće trajanje infuzije od trenutno preporučenog.
English: Anaemia
Croatian: anemija